MODULEX-GRUPPEN
22.5.2024 18:36:27 CEST | Business Wire | Pressemeddelelse
Modulex Gruppen er glade for at kunne annoncere udnævnelsen af Mikkel Arreborg som Chief Finance og Operations Officer med base i koncernens hovedkvarter i Billund. Mikkel har en baggrund som CFO med en dokumenteret track record for strategisk finansielt lederskab og operationel ekspertise på tværs af forskellige brancher.
I løbet af sin tid som CFO hos Auto Solutions Group demonstrerede Mikkel enestående færdigheder i at styre finansielle operationer på tværs af et konglomerat af virksomheder. Hans ansvarsområder omfattede tilsyn med budgettering, finansiel rapportering og aktiv deltagelse i bestyrelsesmøder. Han stod især i spidsen for en omfattende omstrukturering af økonomiafdelingen og implementerede nye systemer og processer for at øge effektiviteten. Mikkel spillede en afgørende rolle i det succesfulde opkøb af Etac Bil i Norge, hvor han viste sin instrumentelle rolle i opkøb og integrationer.
"Det er mig en stor ære at blive en del af Modulex-teamet", siger Mikkel Arreborg. "Jeg er meget begejstret for at deltage i den spændende rejse, der ligger forude for koncernen, og den enestående mulighed for at lære af og bidrage til alle Modulex enheder på tværs af forskellige lande og kulturer."
Før han kom til Modulex Gruppen, havde Mikkel betydelige roller hos bl.a. PwC og BDO. Han har en kandidatgrad i revision og en diplomuddannelse i erhvervsøkonomi med speciale i regnskab og økonomistyring.
Ketil M. Staalesen, CEO i Modulex Gruppen, er begejstret for udnævnelsen af Mikkel og udtaler: "Jeg er virkelig begejstret for, at Mikkel har besluttet sig for at blive en del af vores team. Det er en meget vigtig rolle i fremtiden for den globale koncern, og det er en rolle, jeg arbejder meget tæt sammen med. Jeg var imponeret over Mikkels strategiske sans, hans umiddelbare observation af, hvordan han kunne gøre en forskel, og hans begejstring for at lære og lære alle forretningsenhederne at kende globalt."
Mikkel er en indflydelsesrig leder, der er forpligtet til at fremme et samarbejdsmiljø og bidrage til Modulex' formålsdrevne virksomhedskultur.
For mere information om Modulex, besøg vores hjemmeside https://modulex.com/ eller kontakt vores medierelationsteam på media@modulex.com
Om Modulex Gruppen:
Modulex blev grundlagt i 1963 af LEGO Koncernen og har siden 2009 været ejet af ledende partnere og eksterne investorer og er globalt førende inden for visuel kommunikation. Med rødder i dansk design excellence og et modulært skiltningskoncept har Modulex udviklet sin platform med design, wayfinding, skræddersyede løsninger og brandimplementeringer. I 2019 lancerede Modulex fabrikken i Billund, som er både ISO 9001 og 14001 certificeret, en bæredygtig produktlinje og blev tildelt Green Network-diplomet for 10. gang i træk. Den multinationale koncern har flere produktionsfaciliteter globalt. Koncernen er repræsenteret i over 300 byer i 45 lande.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240522566437/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
